Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Icatibant, ATC B06AC02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 249 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Icatibant, ATC B06AC02

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or maximum framework value provided; potential volume of rebates unknown.

Contract may be automatically terminated if another rebate contract for Icatibant is concluded; uncertainty.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive rebate agreements for the active ingredient Icatibant (ATC B06AC02) under §130a Abs. 8 SGB V.
  • Agreements are identical and non-negotiable; all qualified pharmaceutical companies can participate.
Afficher le résumé complet

AOK Bayern is conducting an open-house model for non-exclusive rebate agreements on the active ingredient Icatibant (ATC B06AC02) under §130a Abs. 8 SGB V. This is not a formal procurement procedure; any interested pharmaceutical company meeting eligibility criteria can conclude an identical, non-negotiable rebate agreement. The contract runs from 01.07.2025 to 30.06.2027, with possible termination on one month's notice. Agreements can be concluded at any time during the period, but no later than 05.05.2027. Submission requires a signed self-declaration of reliability and the signed contract, either in paper form (hand-signed, two copies) or electronically with a qualified electronic signature via the DTVP portal. Only pharmaceutical companies are eligible. Estimated value is not provided.

Risques

No estimated value or maximum framework value provided; potential volume of rebates unknown.

Contract may be automatically terminated if another rebate contract for Icatibant is concluded; uncertainty.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission of the signed contract including the appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Icatibant, ATC B06AC02

Non-exclusive rebate agreements for the active ingredient Icatibant (ATC B06AC02) with AOK Bayern. Open to all interested pharmaceutical companies that meet the eligibility criteria. Identical, non-negotiable terms. Contract duration: 01.07.2025 to 30.06.2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Date limite

Deadline May 05, 2027

Détails de la procédure

Date de publication
15 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
317628-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30